Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 2004;103:1102-1105
© 2004 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bildirici, I
Right arrow Articles by Shumway, J B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bildirici, I
Right arrow Articles by Shumway, J B.
Related Collections
Right arrow Critical Care
Right arrow Internal Medicine
Right arrow Medical complications of pregnancy

CASE REPORTS

Intravenous and Inhaled Epoprostenol for Primary Pulmonary Hypertension During Pregnancy and Delivery

I Bildirici, MD and J B. Shumway, MD, MPH

Department of Obstetrics and Gynecology, Washington University School of Medicine, Barnes Jewish Hospital, St Louis, Missouri

BACKGROUND: Primary pulmonary hypertension carries a significant mortality risk during pregnancy and delivery.

CASE: A 36-year-old pregnant woman with primary pulmonary hypertension was transferred to us with severe dyspnea. Intravenous epoprostenol was started, titrated, and maintained until labor augmentation. Because systemic epoprostenol treatment can interfere with platelet aggregation, we switched to inhaled epoprostenol, administered under a U.S. Food and Drug Administration–approved investigational new drug license, before epidural catheter placement. The inhaled drug was continued because it achieved better control of pulmonary hypertension. An uneventful forceps-assisted vaginal delivery was performed, and intravenous epoprostenol was restarted after the delivery. Mother and baby were well 6 months postpartum.

CONCLUSION: Intravenous epoprostenol treatment is effective in management of pregnant and postpartum women with primary pulmonary hypertension. Inhaled epoprostenol was effective during the intrapartum and immediate postpartum period.




This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
S. Huang and E. R. H. DeSantis
Treatment of pulmonary arterial hypertension in pregnancy
Am. J. Health Syst. Pharm., September 15, 2007; 64(18): 1922 - 1926.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American College of Obstetricians and Gynecologists.